Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription

1 Jun 1990

Abstract excerpt

The antitumor agent camptothecin stabilizes type I topoisomerase-DNA complexes. One of the primary cellular responses to camptothecin exposure is rapid cessation of RNA synthesis. Results obtained by using an in vitro transcription system supplemented with eukaryotic topoisomerase I show that this inhibition can be attributed to physical blockage of the RNA polymerase by camptothecin-stabilized topoisomerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Cancer therapeutics and mechanisms
Share to Neutropenia and Cancer Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1696837
DOI: 10.1021/bi00475a028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcriptionPMID 1696837Read ↗

Genome-Wide Transcriptional Effects of the Anti-Cancer Agent CamptothecinSemantic proximity Read ↗

DNA Damage and Cell Killing by Camptothecin and Its Derivative in Human Leukemia HL‐60 CellsSemantic proximity Read ↗

The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1α Activity by Changing miR Expression Patterns in Human Cancer CellsSemantic proximity Read ↗

The Current Status of Camptothecin Analogues as Antitumor AgentsSemantic proximity Read ↗

An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.Semantic proximity Read ↗

Inhibition of DNA replication in camptothecin-treated cells is regulated by protein kinases.Semantic proximity Read ↗

DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1α gene locusSemantic proximity Read ↗

RNA Polymerase II Blockage by Cisplatin-damaged DNASemantic proximity Read ↗

Current Status and Perspectives in the Development of CamptothecinsSemantic proximity Read ↗

DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.Semantic proximity Read ↗

Effects of mutations in the F361 to R364 region of topoisomerase I (Topo I), in the presence and absence of 9-aminocamptothecin, on the Topo I-DNA interaction.Semantic proximity Read ↗

Inhibition of Human Immunodeficiency Virus (HTV-1) Replication In Vitro by Noncytotoxic Doses of Camptothecin, a Topoisomerase I InhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.